(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 24^th February, 2016

ORDER

S.O. 579(E) – In order to implement the directions given in review order no. 31015/7/2013-PI.I dated 07.10.2015 passed by the Department of Pharmaceuticals for M/s Ranbaxy Laboratories Limited (now M/s Sun Pharmaceutical Industries Ltd.) for fixation/revision of retail prices of Histac EVT tablet (2’s) against price order dated 14.02.2007 in respect of Ranitidine based formulation and Fucibet cream 15gm tube against order dated 3.8.2009 in respect of Betamethasone based formulation under Drugs (Prices Control) Order, 1995 and in exercise of the powers, conferred by sub-paragraph (1)/(2)/(4)/(7) of paragraph 8 of the DPCO 1995 read with S.O. No. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the NPPA, hereby revises the prices as specified in column (5) of the table herein below as the revised retail price, exclusive of Excise duty, Sales Taxes/VAT and local taxes, if any, in relation to each of the formulations specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s Ranbaxy Laboratories Limited (now M/s Sun Pharmaceutical Industries Ltd.)

TABLE

Note :

1. The prices fixed are the revised retail prices in column no. (5) (Exclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
2. The manufacturer/marketing company may add taxes only, if they have paid actually to the Government on the price mentioned in column (5).
3. For different packing material used or, different drug delivery systems or any other special features/forms claimed, the retail prices, as specified in Column No. 5 above, shall be applicable unless the manufacture/marketing company approaches NPPA for specific price approvals for its formulations.
4. The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
5. These revised prices shall be made effective from date of this order as required under paragraph 14(1) of the DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of DPCO, 1995.
6. These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
7. The manufacturer or marketing company not complying with the retail prices and conditions specified in notes hereinabove from the date of this order/notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the Essential Commodities Act, 1955.

PN/158/26/2016/F

F. No. 8(26)/2016/D.P./NPPA-Div.-II
(BALJIT SINGH)
Assistant Director